Following graduation from Fuqua, Rob accepted a position to work at Eli Lilly and Company. Currently, Rob is a Director of Finance for the Lilly BioMedicines Business Unit and serves in consolidating global business unit performance and is the CFO for Development within the business unit. Additionally, he facilitates business development transactions as they evolve and manages the financial integration following deal execution.
Prior to this position, Rob was a director in the mergers and acquisitions group, a Six Sigma Black Belt, and worked as the Debt Capital Markets Analyst in Treasury. Prior to The Fuqua School of Business, Rob worked for five years as a Molecular Biologist at Pfizer and for one year at Affymax. He has a BS in Human Biology from the University of Wisconsin-Green Bay and an MS in Microbiology from Miami University.